• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEL AM filed by BioHarvest Sciences Inc.

    8/28/25 4:13:04 PM ET
    $BHST
    Get the next $BHST alert in real time by email
    DEL AM 1 bhsc_delam.htm DELAYING AMENDMENT Delaying Amendment

     

    BioHarvest Sciences Inc.

    1140-625 Howe Street

    Vancouver, British Columbia

    V6C 2T6, Canada

    (604) 689-5722

     

     

    August 28, 2025

     

    VIA EDGAR

     

    United Stated Securities and Exchange Commission

    100 F Street, N.E.

    Washington, DC 20549

     

    Re:Delaying Amendment for BioHarvest Sciences Inc. 

    Registration Statement on Form S-3 

    File No. 333-289908 

     

    Ladies and Gentlemen:

     

    Reference is made to the Registration Statement on Form S-3 (File No. 333-289908) filed with the Securities and Exchange Commission (the “Commission”) by BioHarvest Sciences Inc. on August 28, 2025 (the “Registration Statement”). Pursuant to Rule 473(c) of the Securities Act of 1933, as amended (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated into the facing page of the Registration Statement:

     

    “The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.”

     

    No fees are required in connection with this filing. If you have any questions or comments in connection with this delaying amendment, please contact our legal counsel Stephen F.X. O’Neill of O’Neill Law LLP at (604) 687-5792.

     

    Sincerely,

     

     

    By: /s/ David K. Ryan

    Name: David K. Ryan

    Title: Vice-President, Investor Relations and Secretary

     

     

    cc:    Stephen F.X. O’Neill of O’Neill Law LLP.

     

     

     

    Get the next $BHST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHST

    DatePrice TargetRatingAnalyst
    5/5/2025$15.00Buy
    Craig Hallum
    12/18/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $BHST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on BioHarvest Sciences with a new price target

    Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00

    5/5/25 8:30:45 AM ET
    $BHST

    Maxim Group initiated coverage on BioHarvest Sciences with a new price target

    Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00

    12/18/24 8:10:03 AM ET
    $BHST

    $BHST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BHST
    SEC Filings

    View All

    BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and Additional $3.8 Million in Debt Reduction

    Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the Company's balance sheet with an additional $10.9 Million in gross proceeds and a concurrent $3.8 Million reduction in total debt.The following are the transactions which were executed subsequent to the Company's published Q2 2025 Financial Statements:Successfully raised $5.8 Million in incremental cash through the exercising of 898,277 w

    9/22/25 6:32:00 AM ET
    $BHST

    BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale

    Exosomes Produced in the Liquid Media of the BioHarvest Unique Large-Scale Bioreactors Add Potential New Revenue Stream from Products and CDMO OpportunitiesRehovot, Israel--(Newsfile Corp. - September 10, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and in its ability to generate new revenue streams.Exosomes are nano-sized extracellular vesicles naturally secreted by plant cel

    9/10/25 7:00:00 AM ET
    $BHST

    BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET

    Rehovot, Israel--(Newsfile Corp. - September 2, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will host a Virtual Investor Webinar on Wednesday, September 10, 2025 at 1:00 p.m. Eastern time.CEO Ilan Sobel will host the virtual investor webinar to provide a corporate update on new capability-building initiatives, the Company's 'Big Bets' for 2H 2025, and will conclude with a question-and-answer session from dial-in participants. To attend, please reference the access information below: Virtual Investor WebinarDate: Wednesday, September 10, 20

    9/2/25 8:30:00 AM ET
    $BHST

    SEC Form 424B7 filed by BioHarvest Sciences Inc.

    424B7 - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    10/15/25 5:17:08 PM ET
    $BHST

    SEC Form 424B7 filed by BioHarvest Sciences Inc.

    424B7 - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    9/24/25 4:38:27 PM ET
    $BHST

    SEC Form 6-K filed by BioHarvest Sciences Inc.

    6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    9/23/25 3:41:41 PM ET
    $BHST

    $BHST
    Leadership Updates

    Live Leadership Updates

    View All

    BioHarvest Announces Appointment of Sharon Malka to Board of Directors

    Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division

    1/22/25 8:30:00 AM ET
    $BHST

    $BHST
    Financials

    Live finance-specific insights

    View All

    BioHarvest Sciences Reports Second Quarter 2025 Financial Results

    Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product SalesRehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025.Second Quarter 2025 HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the second quarter of 2025 increased 41% year-over-year to $8.5 million, in line with management guidance, with gross margins of 60% expanding by 800 basis points y

    8/11/25 7:30:00 AM ET
    $BHST

    BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.m. Eastern Time

    Rehovot, Israel--(Newsfile Corp. - August 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the second quarter ended June 30, 2025 before market open on Monday, August 11, 2025.Management will host an investor conference call and webcast at 8:00 a.m. Eastern time on Monday, August 11, 2025 to discuss the Company's second quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:Second Q

    8/4/25 8:30:00 AM ET
    $BHST

    BioHarvest Sciences Reports First Quarter 2025 Financial Results

    First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

    5/15/25 4:05:00 PM ET
    $BHST